The Psychiatry Consortium aims to deliver treatments for the behavioural symptoms affecting people with dementia.
Many people don’t realise that there are psychiatric symptoms associated with dementia. These symptoms include anxiety, aggression and depression and are particularly devastating.
These are the symptoms that often affect the family and loved ones of the person with the dementia the most. Drugs like antipsychotics do exist to treat some of these behavioural symptoms, but they have significant side effects.
The aim of the Psychiatry Consortium is to deliver new drugs for the behavioural symptoms with dementia. It will provide £3 million in research funding over a three-year period to bring together leading researchers in universities across the world with UK-based drug discovery experts to develop new treatments.
The Psychiatry Consortium unites Alzheimer’s Research UK, Medicines Discovery Catapult and MQ: Transforming mental health. The Wellcome Trust is supporting the project and the major pharmaceutical experts engaged as founding members include: Biogen, Boehringer Ingelheim, Johnson & Johnson Innovation Limited, Lundbeck, MSD and Takeda.
You can read more about the announcement of the Psychiatry Consortium here.
Find out more about our other life-changing drug discovery initiatives here.
New £3 million drug discovery programme for people affected by dementia
Medicines Discovery Catapult, MQ: Transforming mental health and Alzheimer’s Research UK, announce strategic collaboration to create drug discovery Psychiatry Consortium to address unmet patient needs.
